Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France
暂无分享,去创建一个
J. Golmard | F. Goldwasser | G. Orvoen | B. Blanchet | G. Noé | A. Thomas-Schoemann | P. Boudou-Rouquette | M. Vidal | J. Alexandre | O. Huillard | C. Bonnet | C. Villeminey | E. Carton | A. Chah Wakilian | Esther Azoulay-Rutman
[1] J. Snoeys,et al. In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity , 2016, Drug Metabolism and Disposition.
[2] S. Berry,et al. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate , 2016, European Journal of Clinical Pharmacology.
[3] D. Somford,et al. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide , 2016, Clinical Pharmacokinetics.
[4] C. Kollmannsberger,et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer , 2015, Journal of clinical pharmacology.
[5] Justin Fongemie,et al. A Review of Nebivolol Pharmacology and Clinical Evidence , 2015, Drugs.
[6] P. Neuvonen,et al. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol , 2015, European Journal of Clinical Pharmacology.
[7] T. Beer,et al. Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents , 2014, Drugs & Aging.
[8] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[9] Siran Koroukian,et al. Patient Characteristics Associated with Polypharmacy and Inappropriate Prescribing of Medications among Older Adults with Cancer. , 2012, Journal of geriatric oncology.
[10] G. Petersson,et al. Factors leading to excessive polypharmacy. , 2012, Clinics in geriatric medicine.
[11] Y. Daali,et al. Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview. , 2012, Basic & clinical pharmacology & toxicology.
[12] J. Lees,et al. Polypharmacy in elderly patients with cancer: clinical implications and management. , 2011, The Lancet. Oncology.
[13] S. Goutelle,et al. Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions , 2011, Clinical pharmacokinetics.
[14] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[15] M. Extermann,et al. Comprehensive geriatric assessment for older patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Bernard,et al. Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin , 2015, Clinical pharmacology in drug development.
[17] F. Goldwasser,et al. Drug interactions with solid tumour-targeted therapies. , 2014, Critical reviews in oncology/hematology.
[18] A. Tolcher,et al. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer , 2012, Cancer Chemotherapy and Pharmacology.
[19] K. Yap,et al. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. , 2009, Clinical therapeutics.